Abstract
BACKGROUND: Sarcopenia is an age-related degenerative disorder characterized by a progressive decline in skeletal muscle mass, strength, and function with high prevalence in chronic kidney disease (CKD). Identifying clinical and epidemiological factors of sarcopenia in patients with CKD is essential to enable early recognition and appropriate clinical interventions. METHODS: We conducted a systematic search for resources from PubMed, Embase, Web of Science, Wangfang, VIP (China Science and Technology Journal Database), CNKI (National Knowledge Infrastructure), CMAJD (Chinese Medical Association Journal Database), and SinoMed databases until 21 May 2025. We included studies that reported risk factors for sarcopenia in patients with CKD. All data were extracted independently by two reviewers using a standardized data collection form. The odds ratio (OR) for each risk factor was combined from the included studies. Sensitivity analyses and additional subgroup analyses were conducted. RESULTS: Finally 58 studies involving a total of 15 425 participants were included. Risk factors with a significant association with sarcopenia in patients with CKD included diabetes (OR = 1.96; 95% CI: 1.51-2.54; p < 0.001). In contrast, higher BMI (per 1 kg/m(2)) (OR = 0.76; 95% CI: 0.65-0.88; p < 0.001) was associated with a lower risk. In addition, for non-dialysis-dependent CKD (NDD-CKD) patients, older age (per 1 year), diabetes, and higher C-reactive protein (per 1 mg/L) were associated with an increased risk of sarcopenia. In contrast, higher BMI (per 1 kg/m(2)), higher carbon dioxide binding capacity (per 1 mmol/L), and an increase in body protein content (per 1 kg) were protective in this group. In haemodialysis (HD) patients, diabetes and higher body protein content (per 1 kg) were associated with an increased risk of sarcopenia. While higher BMI (per 1 kg/m(2)), higher carbon dioxide binding capacity (per 1 mmol/L), and regular exercise were protective in this group. In renal transplant recipients (RTR), longer dialysis vintage (per 1 month) was identified as a protective factor. CONCLUSION: This study comprehensively illustrated that the development of sarcopenia in patients with CKD is influenced by a variety of risk factors across various domains. The identification of patients at a high risk of sarcopenia who could benefit from enhanced prophylaxis and treatment can be facilitated by the knowledge of risk factors that have a strong association with sarcopenia in patients with CKD. It is imperative to prioritize the identification of modifiable risk factors in order to enhance the effectiveness of prevention and treatment.